'Litfulo Capsules' for Severe Alopecia Areata Treatment Recognized as Eligible for Reimbursement
HIRA's Drug Reimbursement Evaluation Committee Approves Coverage
'Litfulo Capsules, used to treat severe alopecia areata (active ingredient: ritlecitinib tosylate)' have been recognized as eligible for reimbursement under the National Health Insurance.
The Health Insurance Review and Assessment Service announced that, at its 11th Drug Reimbursement Evaluation Committee meeting of the year, held on November 5, the committee reviewed the reimbursement eligibility of Pfizer Korea's Litfulo Capsules 50 mg and voted that they were appropriate for coverage.
Litfulo Capsules are an oral medication used to treat severe alopecia areata in adults and adolescents aged 12 and older.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
After passing review by the Drug Reimbursement Evaluation Committee, the medication's final reimbursement listing will be determined following price negotiations with the National Health Insurance Service and a resolution by the Health Insurance Policy Deliberation Committee of the Ministry of Health and Welfare.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
